Article

Preliminary Results of ERAS Protocol in a Single Surgeon Prospective Case Series

Gabriele Tulone 1,*, Nicola Pavan 1, Alberto Abrate 2, Ettore Dalmasso 3, Piero Mannone 1, Davide Baiamonte 1, Sofia Giannone 1, Rosa Giaimo 1, Marco Vella 1, Carlo Pavone 1, Riccardo Bartoletti 4, Vincenzo Ficarra 5 and Alchiede Simonato 1

1 Section of Urology, Department of Surgical Oncological and Stomatological Sciences, University of Palermo, 90127 Palermo, Italy
2 Urology Unit, Department of Surgery, ASST Valtellina e Alto Lario, 23100 Sondrio, Italy
3 Urology Unit, Department of Surgery, S. Croce e Carle Hospital, 12100 Cuneo, Italy
4 Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56124 Pisa, Italy
5 Urology Unit, Department of Surgery, University of Messina, 98125 Messina, Italy
* Correspondence: gabriele.tulone@gmail.com

Abstract: Background and Objectives: The aim was to compare the intra and postoperative outcomes between the Enhanced Recovery After Surgery (ERAS) protocol versus the standard of care protocol (SCP) in patients who underwent radical cystectomy performed by a single surgeon. Materials and Methods: A retrospective comparative study was conducted including patients who underwent radical cystectomy from 2017 to 2020. Length of stay (LOS), incidence of ileus, early postoperative complications, and number of re-hospitalizations within 30 days were considered as primary comparative outcomes of the study. Results: Data were collected for 91 patients who underwent cystectomy, and 70 and 21 patients followed the SCP and ERAS protocol, respectively. The mean age of the patients was 70.6 (SD 9.5) years. Although there was a statistically significant difference in time to flatus (TTF) [3 (2.7–3) vs. 1 (1–2 IQR) days, \( p < 0.001 \), in the SC hospital and in the ERAS center respectively], no difference was reported in time to first defecation (TTD) [5 (4–6) vs. 4 (3–5.8), \( p = 0.086 \) respectively]. The median LOS in the SCP group was 12 (IQR 11–13) days vs. 9 (IQR 8–13 days, \( p = 0.024 \)). In the postoperative period, patients reported 22 complications (37% in SCP and 42.8% in ERAS group, \( p = 0.48 \)). Conclusions: The study reveals how even partial adherence to the ERAS protocols leads to similar outcomes when compared to SCP. As a single surgeon series, our study confirmed the role of surgeons in reducing complications and improving surgical outcomes.

Keywords: enhanced recovery after surgery; outcomes; ERAS; radical cystectomy; bladder cancer

1. Introduction

Radical cystectomy (RC) with pelvic lymph node dissection is the gold standard treatment for muscle-invasive bladder cancer [1–3]. This procedure, despite the surgical experience gained over the years, is not free from complications both during the operative practice and peri- and postoperative time. The interest of research in the urological field is focused on finding a common guideline for the management of patients who undergo RC to improve the postoperative recovery. Enhanced recovery after surgery (ERAS) [4,5], theorized by Kehlet, consists of evidence-based interventions applied during pre-, intra- and postoperative time to reduce the physical stress due to surgery, to accelerate patient rehabilitation, and reduce hospitalization time. Although the ERAS protocol was born for colorectal surgery, several studies have shown a possible role of this protocol, even in the case of RC, the postoperative recovery [6]. This study aims to compare patients who underwent cystectomy who followed the ERAS protocol with patients who followed the...
usual care protocol analyzing the return to normal bowel functions, length of stay, and early- and late-postoperative complication incidence.

2. Materials and Methods

A retrospective comparative study was conducted including consecutive patients who underwent radical cystectomy in two urological centers. We collected the data regarding the hospitalization of patients undergoing RC, with an open approach in a standard care center from 2017 to 2019 (non-ERAS protocol), and the data of patients from a second center undergoing the same surgery, but with a certified ERAS protocol. The ERAS certification was achieved in 2020 (ERAS items are present in Table 1, according to the ERAS guidelines). Inclusion criteria were consecutive patients who underwent RC for muscle invasive bladder cancer performed by the same surgeon. For each patient, all of the preoperative characteristics such as age, sex, comorbidities, blood tests, ECOG (Eastern Cooperative Oncology Group), ASA (American Society of Anesthesiologists), and CCI (Charlson Comorbidity Index) were considered. We compared the postoperative parameters of the two centers (ERAS and non-ERAS) analyzing the differences in length of stay (LOS), time to flatus (TTF), time to defecation (TTD), presence of ileus, positioning of the nasogastric tube (NGT) and its maintaining time, onset of complications, early or late, using the Clavien–Dindo (CD) score, and the presence of re-hospitalizations. The study was conducted on the available retrospective data and according to our ethical committee, approval is not required.

Table 1. A summary of each ERAS item and their respective level of evidence and grade of recommendation derived from both the cystectomy and the colorectal literature.

| ERAS Single Item                      | Summary                                                                 | Specifics for Cystectomy Patients/Open Questions                                                                 | Evidence for Cystectomy/Rectal Surgery | Grade of Recommendation |
|--------------------------------------|-------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|---------------------------------------|--------------------------|
| 1. Preoperative counseling and education | Preoperative counseling and education                                    | Surgical details, hospital stay, and discharge criteria in oral and written form; stoma education; patient’s expectations. | Na/Low                              | Strong                   |
| 2. Preoperative medical optimization  | Preoperative optimization of medical conditions should be recommended. Preoperative nutritional support should be considered, especially for malnourished patients | Correction of anemia and co-morbidities; Nutritional support; Smoking cessation and reduction of alcohol intake 4 weeks prior to surgery; encouraging physical exercise. | Na/Moderate Na/Moderate Na/Very low Na/High | Strong                   |
| 3. Oral mechanical bowel preparation  | Preoperative bowel preparation can be safely omitted                    | /                                                                                                              | Moderate/High                        | Strong                   |
| 4. Preoperative carbohydrates loading | Preoperative oral carbohydrate loading should be administered to all non-diabetic patients | /                                                                                                              | Na/Low                               | Strong                   |
| 5. Preoperative fasting               | Intake of clear fluids up until 2 h before induction of general anesthesia is recommended. Solids are allowed up until 6 h before anesthesia. | /                                                                                                              | Na/Moderate                          | Strong                   |
### Table 1. Cont.

| ERAS Single Item | Summary | Specifics for Cystectomy Patients/Open Questions | Evidence for Cystectomy/Rectal Surgery | Grade of Recommendation |
|------------------|---------|-------------------------------------------------|---------------------------------------|-------------------------|
| 6. Preanesthesia medication | Avoidance of long-acting sedatives | / | Na/Moderate | Strong |
| 7. Thrombosis prophylaxis | Patients should wear well-fitting compression stockings, and receive pharmacological prophylaxis with LMWH. Extended prophylaxis for 4 weeks should be carried out in patients at risk. 12 h interval between injections and epidural manipulation | Cystectomy patients are considered at risk; prolonged prophylaxis should therefore be administered | Na/High | Strong |
| 8. Epidural analgesia | Thoracic epidural analgesia is superior to systemic opioids in relieving pain. It should be continued for 72 h | / | Na/High | Strong |
| 9. Minimally invasive approach | At most feasible; in trial setting Long term oncological results awaited | Laparoscopic/robotic cystectomy is not recommended outside a trial setting until long term results are available. | Low/Moderate | Strong |
| 10. Resection site drainage | Perianastomotic and/or pelvic drain can be safely omitted. | Because of urine leak, drainage might be required in cystectomy patients. | Na/Low | Weak |
| 11. Antimicrobial prophylaxis and skin preparation | Patient should receive a single dose antimicrobial prophylaxis 1 h before skin incision. Skin preparation with chlorexidine-alcohol prevents/decreases surgical site infection. | / | Na/High Na/Moderate | Strong |
| 12. Standard anesthetic protocol | To attenuate the surgical stress response, intraoperative maintenance of adequate hemodynamic control, central and peripheral oxygenation, muscle relaxation, depth of anesthesia, and appropriate analgesia is recommended. Fast acting agents? | / | Na/Moderate | Strong |
| ERAS Single Item | Summary | Specifics for Cystectomy Patients/Open Questions | Evidence for Cystectomy/Rectal Surgery | Grade of Recommendation |
|------------------|---------|-----------------------------------------------|--------------------------------------|------------------------|
| 13. Perioperative fluid management | Fluid balance should be optimized by targeting cardiac output using the esophageal Doppler system or other systems for this purpose and avoiding overhydration. | High-risk patients need close and individualized goal directed fluid management. There are several ways to achieve this and all must be used together with sound clinical judgment. | Low/High | Strong |
| 14. Preventing intraoperative hypothermia | Normal body temperature should be maintained per-and postoperatively. | Especially relevant for cystectomy patients since operative duration is prolonged | Na/high | Strong |
| 15. Nasogastric intubation | Postoperative nasogastric intubation should not be used routinely. | Early removal is recommended. | Low/High | Strong |
| 16. Urinary drainage | Transurethral catheter can be removed on postoperative day 1 after pelvic surgery in patients with a low risk of urinary retention. | Ureteral stents and transurethral neo-bladder catheter should be used. The optimal duration of ureteral stenting (at least until POD 5) and transurethral catheterization is unknown. | Very low/Low | Weak |
| 17. Prevention of postoperative ileus | A multimodal approach to optimize gut function should involve gum chewing and oral magnesium. | / | Moderate/Moderate | Strong |
| 18. Prevention of PONV | A multimodal PONV prophylaxis should be adopted in all patients with ≥2 risk factors. | Multimodal prophylaxis. | Very low/Low (High in high-risk patients) | Strong |
| 19. Postoperative analgesia | A multimodal postoperative analgesia | / | Very low/Low (High in high-risk patients) | Strong |
| 20. Early mobilization | Early mobilization should be encouraged | 2 h out of bed POD 0; 6 h out of bed POD 1. | Na/High | Strong |
| 21. Early oral diet | Early oral nutrition should be started 4 h after surgery | / | Na/Moderate | Strong |
| 22. Audit | All patients should be audited for protocol compliance and outcome | Routine audit of outcomes, cost-effectiveness, compliance and changes in protocol. | Na/Low | Strong |

Na: not available; ERAS: enhanced recovery after surgery; LMWH: low molecular weight heparin; PONV: postoperative nausea and vomiting; POD: postoperative day.
Statistical Analysis

The means and standard errors of the mean were reported for continuous variables assumed to be normally distributed. The remaining continuous variables were summarized by their median values and interquartile ranges. Data are compared with the Student’s t-test, Mann–Whitney, and Chi-square for the normal, non-normal, and nominal variables, respectively. A value of p < 0.05 was considered significant. The sample size was not calculated because of the retrospective nature of the study.

3. Results

Data were collected from 91 consecutive patients who underwent cystectomy, 70 of them followed the standard care protocol (SCP) and 21 the ERAS protocol. The mean age of the patients was 70.6 ± 9.5 years. Pre-operative blood analyses of the two subgroups did not demonstrate statistically significant differences except for the albumin serum levels, which was higher in the SPC center (Table 2). There was a statistically significant difference between the incidences of comorbidities, with a greater rate of in-patients treated with the SCP (78.5% vs. 28.5%, p < 0.001). The performance status was evaluated with the ECOG score (Table 3. The ASA score was higher in the SCP patients (ASA ≥ 3: 97.1% vs. 47.6%). Operating time (OR) and estimated blood loss (EBL) were also reported in Table 2. Although there was a statistically significant difference in TTF (3 (2.7–3) vs. 1 (1–2) IQR 4.3–9.8) in the SCP and ERAS groups, respectively (p = 0.01), there was a difference in the ileus rate, with a higher incidence in the ERAS center (23.8 % vs. 4.1 %, p = 0.037) (Table 4). The percentage of patients without postoperative NGT is significantly different between the two groups (10.2% vs. 90.4% in non-ERAS centers and in the ERAS patients, respectively). This can be explained by the fact that in the SPC center, the NGT was routinely inserted and maintained after the surgical procedure. There was a difference in the ileus rate, with a higher incidence in the ERAS center (23.8 % vs. 4.1 %, p = 0.037) (Table 4). The difference can be explained by the fact that NGT was routinely inserted and maintained in the SPC center, reducing the rate of postoperative nausea. The median length of stay (LOS) of patients in the non-ERAS center was 12 days (IQR 11–13) and in the ERAS center, it was 9 days (IQR 8–13.4) (p = 0.024). In the postoperative period, 22 (37%) complications have been recorded in the non-ERAS center (68% grade 1 and 2 according to the Clavien–Dindo classification), while nine (43%) complications were recorded in the ERAS center (100% grade 1, 2) without significant differences between the two groups (p = 0.48). Table 4 reports the rate of postoperative complications according to CD classification. According to these findings, the incidence rate of late postoperative complications was significantly higher in the ERAS patients compared to the usual care patients (35% vs. 12.2%, respectively; p = 0.03). The mean follow-up time after surgery was 15.8 (IQR 7.3–21.8) months and 7 (IQR 4.3–9.8) in the SCP and ERAS groups, respectively (p = 0.01).

Figure 1. The standard care protocol vs. the ERAS protocol: LOS, TTD, TTF.
Table 2. The patient characteristics.

| Variable                | Total  | Standard | ERAS  | p-Value |
|-------------------------|--------|----------|-------|---------|
| Patients                | 91     | 70 (76.9)| 21 (23.1) |         |
| Age, year               | 70.6 ± 9.5 | 69.3 ± 9.6 | 74.9 ± 7.7 | 0.016   |
| BMI, kg/m²              | 26.2 ± 4.2 | 26.4 ± 4.3 | 25.7 ± 4.1 | 0.538   |
| Gender                  |        |          |       |         |
| Female                  | 13 (14.3) | 10 (14.2) | 3 (14.3) | 0.722   |
| Male                    | 78 (85.7) | 60 (85.8) | 18 (85.7) |         |
| ECOG performance status |        |          |       |         |
| 0                       | 27 (33.7) | 23 (32.8) | 4 (40) | 0.801   |
| 1                       | 51 (63.7) | 45 (64.2) | 6 (60) |         |
| 2                       | 2 (2.5) | 2 (3) | 0 (0) |         |
| Comorbidities           |        |          |       |         |
| No                      | 30 (33.0) | 15 (21.4) | 15 (71.4) | <0.001  |
| Yes                     | 61 (67.0) | 55 (78.6) | 6 (28.6) |         |
| Hypertension            |        |          |       |         |
| No                      | 47 (51.6) | 30 (42.8) | 17 (81) | 0.005   |
| Yes                     | 44 (48.4) | 40 (57.2) | 4 (19) |         |
| Diabetes                |        |          |       |         |
| No                      | 63 (69.2) | 46 (65.7) | 17 (81) | 0.290   |
| Yes                     | 28 (30.8) | 24 (34.3) | 4 (19) |         |
| COPD                    |        |          |       |         |
| No                      | 76 (83.5) | 55 (78.5) | 21 (100) | 0.047   |
| Yes                     | 15 (16.5) | 15 (21.5) | 0 (0) |         |
| Cardiopathy             |        |          |       |         |
| No                      | 66 (72.5) | 46 (65.7) | 20 (95.2) | 0.017   |
| Yes                     | 25 (27.5) | 24 (34.3) | 1 (4.8) |         |
| ASA score               |        |          |       |         |
| 2                       | 13 (14.3) | 2 (2.8) | 11 (52.3) | <0.001  |
| 3                       | 67 (73.6) | 57 (81.4) | 10 (47.7) |         |
| 4                       | 11 (12.1) | 11 (15.8) | 0 (0) |         |
| Charlson CI             | 6 (5–6) | 6 (5–6) | 6 (4.6–6.4) | 0.913   |
| OR, min                 | 273 (212–334) | 286 (223–348) | 231 (194–268) | <0.001  |
| EBL, mL                 | 399 (380–588) | 431 (239–623) | 290 (157–423) | <0.001  |

Continuous variables were expressed as the mean ± SD or median (IQR); nominal variables were expressed as No. (%). ERAS: enhanced recovery after surgery; BMI: body mass index; ECOG: Eastern Cooperative Oncology Group performance status; COPD: Chronic obstructive pulmonary disease; ASA: American Society of Anesthesiologists; OR: operating time EBL: estimated blood loss.

Table 3. The pre-operative blood analyses.

| Variable                | Total   | Standard | ERAS   | p-Value |
|-------------------------|---------|----------|--------|---------|
| Hb, g/dL                | 13.0 ± 1.8 | 13.1 ± 1.8 | 12.8 ± 1.7 | 0.596   |
| Neutrophils, ×10³/µL    | 5.6 ± 2.5 | 5.8 ± 2.5 | 4.9 ± 1.9 | 0.287   |
| Lymphocytes, ×10³/µL    | 1.9 ± 0.6 | 1.9 ± 0.6 | 1.9 ± 0.6 | 0.920   |
| Platelets, ×10³/µL      | 271 ± 98 | 271 ± 100 | 269 ± 86 | 0.946   |
| Creatinine, mg/dL       | 1.1 ± 0.8 | 1.2 ± 0.9 | 1.0 ± 0.3 | 0.103   |
| Albumin, g/L            | 39.0 ± 6.2 | 39.9 ± 6.0 | 32.5 ± 3.2 | <0.001  |

Continuous variables were expressed as the mean ± SD or median (IQR); nominal variables were expressed as No. (%).
Table 4. The postoperative characteristics.

| Variable                                      | Total     | Standard | ERAS       | p-Value |
|-----------------------------------------------|-----------|----------|------------|---------|
| Length of stay (LOS), days                    | 11 (10–13)| 12 (11–13)| 9 (8–13.4) | 0.024   |
| Time to the first defecation (TTD), days      | 5 (4–5.3)| 5 (4–6)  | 4 (3–5.8)  | 0.086   |
| Time to the first flatus (TTF), days          | 2 (2–3)  | 3 (2.7–3)| 1 (1–2)    | <0.001  |
| Ileus                                         |           |          |            |         |
| No                                            | 63 (90.0)| 47 (95.9)| 16 (76.2)  | 0.037   |
| Yes                                           | 7 (10.0) | 2 (4.1)  | 5 (23.8)   |         |
| NGT (nasogastric tube) placement              |           |          |            |         |
| No                                            | 21 (28.0)| 7 (12.5) | 14 (73.6)  | <0.001  |
| <48 h                                         | 25 (33.3)| 21 (37.5)| 4 (21)     |         |
| >48 h                                         | 29 (38.7)| 28 (50) | 1 (5.4)    |         |
| Postoperative NGT                             |           |          |            |         |
| No                                            | 24 (32.0)| 5 (9.2)  | 19 (90.4)  | <0.001  |
| Yes                                           | 51 (68.0)| 49 (90.8)| 2 (9.6)    |         |
| Early complications                           |           |          |            |         |
| No                                            | 60 (65.9)| 48 (68.5)| 12 (57.1)  | 0.480   |
| Yes                                           | 31 (34.1)| 22 (31.5)| 9 (42.9)   |         |
| Early complications Clavien–Dindo             |           |          |            |         |
| No                                            | 58 (63.7)| 47 (67.1)| 11 (52.3)  | 0.098   |
| 1                                             | 7 (7.7)  | 6 (8.5)  | 1 (4.7)    |         |
| 2                                             | 17 (18.7)| 9 (11.1) | 8 (38.3)   |         |
| 3                                             | 6 (6.6)  | 6 (8.5)  | 0 ()       |         |
| 4                                             | 1 (1.1)  | 1 (1.4)  | 0 ()       |         |
| 5                                             | 2 (2.2)  | 1 (1.4)  | 1 (4.7)    |         |
| Early complications time, days                | 4 (2.2–5.4)| 3 (0–8) | 5 (4–6)   | 0.376   |
| Late complications                            |           |          |            |         |
| No                                            | 57 (82.6)| 43 (87.7)| 14 (70)    | 0.157   |
| Yes                                           | 12 (17.4)| 6 (12.3) | 6 (30)     |         |
| Late complications Clavien–Dindo              |           |          |            |         |
| No                                            | 56 (81.2)| 43 (87.7)| 13 (65)    | 0.003   |
| 1                                             | 1 (1.4)  | 0 ()     | 1 (5)      |         |
| 2                                             | 3 (4.3)  | 0 ()     | 3 (15)     |         |
| 3                                             | 7 (10.1)| 6 (12.3) | 1 (5)      |         |
| 4                                             | 0       | 0 ()     | 0 ()       |         |
| 5                                             | 2 (2.9) | 0 ()     | 2 (10)     |         |
| Late complications time, days                 | 38.5 (29.7–122.6)| 34.5 (22.3–157.1)| 51 | 0.505 |

Continuous variables were expressed as the mean ± SD or median (IQR); nominal variables were expressed as No. (%).

4. Discussion

In all surgical areas, there is increasing attention on the hospitalization time, influenced by the onset of postoperative complications. The ERAS protocol was born to improve the clinical outcomes of surgery and reduce the economic pressure of patients in many developing countries [7,8]. Since the introduction of ERAS into colorectal surgery, several preoperative, intraoperative, and postoperative steps have been implemented to improve patient rehabilitation. The benefits of the ERAS protocols are similar in many surgeries such as bariatric, esophageal, and other gastrointestinal surgeries [9–11]. In urological practice, the use of the ERAS protocol is limited for one of the most challenging interventions, both for surgeons and patients, RC. [4,12]. The ERAS protocol consists of 21 items including pre-, intra-, and postoperative approach [6]. The literature refers to many patients undergoing radical cystectomy that benefit from enhancements in perioperative management.
Unfortunately, sometimes, the protocol is hard to apply for its rigidity. The aim of our study was to evaluate the difference in outcome in the usual care patients comparing the ERAS patients and the effectiveness of the ERAS protocol by comparing specific parameters. Our data indicate that there was no substantial improvement in the postoperative course between patients who followed the ERAS protocol and those undergoing usual care. The population examined in the non-ERAS center was characterized by higher comorbidities and higher ASA score. Although the TTF was shorter in patients undergoing the ERAS protocol [3 days (2.7–3) vs. 1 day (1–2) \( p < 0.001 \), respectively], the same cannot be said for the TTD time, which was comparable. The ERAS protocols were also introduced to reduce postoperative ileus [13]. There are many definitions of the ileus in the literature. We defined post operative ileus after radical cystectomy, the reduction in bowel movement, intolerance of oral diet, and vomiting, requiring cessation of oral intake with the necessity of nasogastric tube insertion [14]. There is no univocal criterion for the insertion of NGT, and it is always upon clinical judgment. Standardization would be helpful to compare the results of future studies on postoperative ileus [15]. Our data demonstrated a lower incidence of the ileus in the usual care population compared to the ERAS protocol population. Despite this result, the TTF was significantly shorter in the ERAS group. Another purpose of the ERAS protocol is to minimize the hospitalization time: such a target was confirmed in our study. Furthermore, the hospitalization time is influenced by postoperative complications evaluated with the CD classification, both in the short- and long-term. Furthermore, for this parameter, there is no evidence of substantial and statistically significant differences. Although the ERAS protocol is today of great interest in urological surgery, however, there are conflicting data in the literature on its ability to influence perioperative outcomes [15,16]. Many studies have shown that ERAS courses can reduce the length of stay [15,17–21], while some refute this thesis [21–24]; the same was true in the evaluation of the reduction in time to the recovery of bowel activity and in the readmission rate [19–23,25,26]. The study does not want to discredit the ERAS protocol, but to rather understand whether there are unassessed parameters that could influence the postoperative course. These parameters can be subjective and hardly standardizable as, for instance, the surgeon experience and the number of interventions by the center. The surgical technique, the manual skills, and the number of interventions can influence the operative course as they affect various parameters such as the operative time, the time of ileal–ileal anastomosis and the suture technique, blood losses, and the incidence of intraoperative complications. The high number of interventions of a center is associated with a greater confidence with the type of patient, with their needs, knowledge of time for the postoperative steps such as mobilization, which is essential for a rapid recovery of the patient, and prompt identification of deviations from the patient in a normal postoperative course. This hypothesis was already explored by previous studies and in 2016, Moschini et al. reported the published results into a systematic review [27,28]. According to their results, the surgical volume is affecting outcomes after radical cystectomy in terms of perioperative complications. The main limitation of this study was the initial retrospective design. A larger number of patients needs to be included in future trials to reach significance and stronger results. However, we reported this number of patients because this is exactly the required amount necessary to obtain the ERAS certification.

5. Conclusions

The application of the ERAS protocol in patients undergoing RC should improve the timing of rehabilitation and reduce LOS and the hospitalization costs. Our study surprisingly showed that our surgical technique resized the results expected from the ERAS Society protocol to accelerate the postoperative recovery time and reduce the early- and late-postoperative complications. Therefore, a precise, accurate, and fast surgical procedure with reduced blood loss that tends to minimize postoperative complications is able to determine the patient’s recovery on its own, regardless of strict protocols. In other words,
the ERAS protocols are certainly useful to speed up recovery, but does not seem to be able to disregard a good surgical technique.

Author Contributions: Conceptualization, A.S.; Methodology, G.T.; Formal analysis, N.P.; Investigation, A.A.; Resources, E.D.; Data curation, N.P.; Writing—original draft preparation, G.T., D.B., P.M. and S.G.; Writing—review and editing, V.F., A.S., R.G. and M.V.; Supervision, A.S., C.P., R.B. and V.F. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Ethics Committee of A.O.U. P. Paolo Giaccone of Palermo, Italy. Protocol code 03/2022, date of approval 15 March 2022.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this manuscript are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Donald, E.L. Guidelines for Perioperative Care in Esophagectomy: Enhanced Recovery After Surgery (ERAS®) Society Recommendations. World J. Surg. 2019, 43, 299–330. [CrossRef]
2. Kulkarni, G.S.; Hakenberg, O.W.; Gschwend, J.E.; Thalmann, G.; Kassouf, W.; Kamat, A.; Zlotta, A. An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously T1G3) Bladder Cancer. Eur. Urol. 2010, 57, 60–70. [CrossRef]
3. Khadhouri, S.; Gallagher, K.M.; MacKenzie, K.R.; Shah, T.T.; Gao, C.; Moore, S.; Zimmermann, E.F.; Jefferies, M.; Nambiar, A.; et al. The IDENTIFY study: The investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer—A multicentre observational study. Br. J. Urol. 2021, 128, 440–450. [CrossRef]
4. Cerantola, Y.; Valerio, M.; Persson, B. Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS(®)) society recommendations. Clin. Nutr. 2013, 32, 879–887. [CrossRef] [PubMed]
5. Claps, F.; Mir, M.C.; Zargar, H. Molecular markers of systemic therapy response in urothelial carcinoma. Asian J. Urol. 2021, 8, 376–390. [CrossRef] [PubMed]
6. Chenam, A.; Chan, K.G. Enhanced Recovery after Surgery for Radical Cystectomy. Cancer Treat. Res. 2018, 175, 215–239.
7. Chunxiao, W.; Fengchun, W. Application of enhanced recovery after surgery in patients undergoing radical cystectomy. J. Int. Med. Res. 2018, 46, 5011–5018.
8. Kehlet, H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br. J. Anaesth. 1997, 78, 606–617. [CrossRef]
9. Pisarska, M.; Malczak, P.; Major, P.; Wysocki, M.; Budzyński, A.; Pędziwiatrz, M. Enhanced recovery after surgery protocol in oesophageal cancer surgery: Systematic review and meta-analysis. PLoS ONE 2017, 12, e0174382. [CrossRef]
10. Malczak, P.; Pisarska-Adamczyk, M.; Pietr, M.; Wysocki, M.; Budzyński, A.; Pędziwiatrz, M. Enhanced Recovery after Bariatric Surgery: Systematic Review and Meta-Analysis. Obes. Surg. 2016, 27, 226–235. [CrossRef]
11. Pędziwiatrz, M.; Mavrikis, J.; Witowski, J. Current status of enhanced recovery after surgery (ERAS) protocol in gastrointestinal surgery. Med. Oncol. 2018, 35, 95. [CrossRef] [PubMed]
12. Connor, M.F.; Ali, C.C. Defining postoperative ileus and associated risk factors in patients undergoing radical cystectomy with an Enhanced Recovery AfterSurgery (ERAS) program. Can. Urol. Assoc. 2021, 15, 33–39.
13. Godden, A.R.; Marshall, J.M. Ultrasoundography guided rectus sheath catheters vs. epidural analgesia for open colorectal cancer surgery in a single centre. Ann. R. Coll. Surg. Engl. 2013, 95, 591–594. [CrossRef] [PubMed]
14. Ramirez, J.A.; McIntosh, A.G.; Strehlow, R.; Lawrence, V.A.; Parekh, D.J.; Svatek, R.S. Definition, incidence, risk factors, and prevention of paralytic ileus following radical cystectomy: A systematic review. Eur. Urol. 2013, 64, 588–597. [CrossRef]
15. Pruthi, R.S.; Chun, J.; Richman, M. Reducing time to oral diet and hospital discharge in patients undergoing radical cystectomy using a perioperative care plan. Urology 2003, 62, 661–665. [CrossRef]
16. Xu, W.; Daneshmand, S.; Bazargani, S.T.; Cai, J.; Miranda, G.; Schuckman, A.K.; Djaladat, H. Postoperative Pain Management after Radical Cystectomy: Comparing Traditional versus Enhanced Recovery Protocol Pathway. J. Urol. 2015, 194, 1209–1213. [CrossRef]
17. Arumainayagam, N.; McGrath, J.; Jefferson, K.P.; Gillatt, D.A. Introduction of an enhanced recovery protocol for radical cystectomy. Br. J. Urol. 2008, 101, 698–701. [CrossRef]
18. Daneshmand, S.; Ahmadi, H.; Schuckman, A.K.; Mitra, A.P.; Cai, J.; Miranda, G.; Djaladat, H. Enhanced Recovery Protocol after Radical Cystectomy for Bladder Cancer. J. Urol. 2014, 192, 50–56. [CrossRef]
19. Smith, J.; Meng, Z.W.; Lockyer, R.; Dudderidge, T.; McGrath, J.; Hayes, M.; Birch, B. Evolution of the Southampton Enhanced Recovery Programme for radical cystectomy and the aggregation of marginal gains. Br. J. Urol. 2014, 114, 375–383. [CrossRef]

20. Collins, J.W.; Adding, C.; Hosseini, A.; Nyberg, T.; Pini, G.; Dey, L.; Wiklund, P.N. Introducing an enhanced recovery programme to an established totally intracorporeal robot-assisted radical cystectomy service. Scand. J. Urol. 2015, 50, 39–46. [CrossRef]

21. Guan, X.; Liu, L.; Lei, X. A comparative study of fast-track versus [corrected] conventional surgery in patients undergoing laparoscopic radical cystectomy and ileal conduit diversion: Chinese experience. Sci. Rep. 2014, 4, 6820. [CrossRef] [PubMed]

22. Mukhtar, S.; Ayres, B.E.; Issa, R.; Swinn, M.J.; Perry, M.J.A. Challenging boundaries: An enhanced recovery programme for radical cystectomy. Ann. R. Coll. Surg. Engl. 2013, 95, 200–206. [CrossRef] [PubMed]

23. Cerruto, M.A.; De Marco, V.; D’Elia, C. Fast track surgery to reduce short-term complications following radical cystectomy and intestinal urinary diversion with Vescica Ileale Padovana neobladder: Proposal for a tailored enhanced recovery protocol and preliminary report from a pilot study. Urol. Int. 2014, 92, 41–49. [CrossRef]

24. Persson, B.; Carringer, M.; Andrén, O.; Andersson, S.-O.; Carlsson, J.; Ljungqvist, O. Initial experiences with the enhanced recovery after surgery (ERAS®) protocol in open radical cystectomy. Scand. J. Urol. 2014, 49, 302–307. [CrossRef] [PubMed]

25. Claps, F.; van de Kamp, M.W.; Mayr, R.; Bostrom, P.J.; Boormans, J.L.; Eckstein, M.; Mertens, L.S.; Boevé, E.R.; Neuzillet, Y.; Burger, M.; et al. Risk factors associated with positive surgical margins’ location at radical cystectomy and their impact on bladder cancer survival. World J. Urol. 2021, 39, 4363–4371. [CrossRef]

26. Grass, F.; Sliker, J.; Jurt, J.; Kummer, A.; Solà, J.; Hahnloser, D.; Demartines, N.; Hübner, M. Postoperative ileus in an enhanced recovery pathway—A retrospective cohort study. Int. J. Color. Dis. 2017, 32, 675–681. [CrossRef]

27. Moschini, M.; Simone, G.; Stenzl, A.; Gill, I.S.; Catto, J. Critical Review of Outcomes from Radical Cystectomy: Can Complications from Radical Cystectomy Be Reduced by Surgical Volume and Robotic Surgery? Eur. Urol. Focus 2016, 2, 19–29. [CrossRef]

28. Claps, F.; Rai, S.; Mir, M.C.; van Rhijn, B.W.; Mazzon, G.; Davis, L.E.; Valadon, C.L.; Silvestri, T.; Rizzo, M.; Ankem, M.; et al. Prognostic value of preoperative albumin-to-fibrinogen ratio (AFR) in patients with bladder cancer treated with radical cystectomy. Urol. Oncol. Semin. Orig. Investig. 2021, 39, 835.e9–835.e17. [CrossRef]